BioSpace News Archive

Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.

- Revenue of $1.48 billion, declining 3.5%; organic decline of 2.0% - Net income of $60.2 million; Adjusted EBITDA $273.3 million, Adjusted EBITDA expansion of 94 basis points - Diluted GAAP EPS $0.08; adjusted EPS $0.19, increase of 32.5% - YTD Operating Cash Flow $342.3 million; YTD Free Cash Flow $316.2 million, increase of 641% - Adjusted net leverage of 4.3x from 4.6x at December 31, 2019 - Refinances $2B unsecured notes lowering associated

- Quarterly revenue of $491 million - Semi-Cap revenue growth of 39% year-over-year - Medical revenue growth of 18% year-over-year - Quarterly GAAP diluted loss per share of $(0.09) and non-GAAP diluted EPS of $0.07 - Operating cash flow of $23 million [29-July-2020] TEMPE, Ariz. , July 29, 2020 /PRNewswire/ -- Benchmark Electro

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Canaccord Genuity 40th Annual Growth Conference, to be held virtually on Wednesday, August 13, 2020.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Peyton Howell as an independent member of its board of directors effective August 3, 2020.

Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma.

CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2020.

MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 5, 2020.

Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering

ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA” or “the Company”), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced it intends to release its second quarter, 2020 financial results before market open on Wednesday, August 12, 2020.